Resources Archive - WuXi Biology

Defining the Next Era of Cancer Therapeutics

Building on the momentum of AACR 2026, WuXi AppTec was honored to host an exceptional group of regional industry leaders...

Targeting ER Mutations and Drug Resistance

Targeting ER Mutations and Drug Resistance: R&D Strategies and Comprehensive Preclinical Evaluation of Novel ER Degraders Introduction Estrogen receptor (ER)-positive...

α-Synuclein-Based Animal Models of Parkinson’s Disease

Establishment and Efficacy Evaluation of α-Synuclein-Based Animal Models of Parkinson’s Disease OncoWuXi Express will continue to keep you informed about...

Overcoming Osteoporosis R&D Bottlenecks

Overcoming Osteoporosis R&D Bottlenecks with Multi-Dimensional OVX Models Against the backdrop of an actively aging global population, osteoporosis has emerged...

PD-1 Blockade with a DLL3 TCE Potentiates Efficacy in SCLC

Small cell lung cancer (SCLC) remains one of the most aggressive and difficult-to-treat cancers, highlighting the ongoing need for new...

Novel E3 Ligase to Support Targeted Protein Degradation

Targeted protein degradation (TPD) continues to expand the possibilities for next-generation therapeutics, and identifying novel E3 ligases remains an important...

Mechanistic Profiling of ADC-resistant Cancer Cell Lines

Antibody-drug conjugates (ADCs) have emerged as an important modality in targeted cancer therapy development. However, acquired resistance continues to limit...

Unveiling Mechanisms of MRTX1133 Resistance

Recent years have seen major advances in KRAS G12D-targeted therapeutics. However, acquired drug resistance remains a significant clinical challenge, with...